Do you love radiopharmaceuticals as much as we do? CPDC is always looking for exceptional people to strengthen our team. If you are interested in joining our team or if you would like to learn more about our current or future opportunities please contact firstname.lastname@example.org. Check our list of current opportunities below
The Centre for Probe Development & Commercialization (CPDC) has a unique and exciting opportunity in the areas of engineering and production at our Ottawa site. The Engineering and Production Technologist will be cross trained such that they are able to perform routine manufacturing of radiopharmaceuticals, as well as support maintenance and repair of equipment, including cyclotron systems.Learn more Apply
This position is responsible for technical leadership and project management of CDMO (Contract, Development & Manufacturing Organization) programs. The role will work in collaboration with team members, other departments and customers to ensure successful development, setup, launch and routine manufacturing of radiopharmaceuticals.Learn more Apply
The Centre for Probe Development and Commercialization (CPDC) is dedicated to fostering the development, translation, and commercialization of molecular imaging probes and associated technologies. The Centre is seeking outstanding applicants for a Quality Assurance Associate – 15 month Contract. Overview: The Quality Team is looking for a focused and motivated individual interested in making significant contributions to ensure GMP compliance in development and production of radiopharmaceuticals.Learn more Apply
NSERC Brockhouse Canada Prize Honours Medical Isotope Team CycloMed99 (Vancouver, BC) – For their outstanding teamwork in realizing a solution for safe and reliable isotope production for hospitals in Canada, interdisciplinary research team CycloMed99 will be receiving a prestigious national award at a ceremony in Ottawa today. The Honourable David Johnston, Governor General of Canada,
CPDC’s Discovery Team is experienced in oncology, immuno-oncology, and neurology models.
CPDC and University Health Network have created a joint venture, CanProbe, to accelerate the clinical development of molecular imaging probes.
CPDC’s manufacturing facilities are approved by both Health Canada and the US FDA for the production of positron emitting radiopharmaceuticals.
Global drug companies are using CPDC’s know-how and world-class facilities to develop and test new drugs and molecular probes.
During medical isotope shortages, CPDC can provide substitutes for use in bone scans and imaging kidney function.
CPDC can create PET and SPECT imaging companions for small molecules, peptides, antibodies and other biologics.
CPDC works with all therapeutic and diagnostic isotopes, and has extensive expertise with alpha and beta emitting nuclides.
Cyclotrons can be used to produce enough Tc-99m within 6 hours to enable over 500 nuclear imaging scans.
Molecular imaging probes can show a tumour’s biochemical response to treatment in just a few days, unlike conventional modes like MRI or CT, which may not show a change in tumour size for several weeks.
ARTMS Products Inc. has been created by Triumf, BCCA, LHRI and CPDC to commercialize jointly-developed technology for production of Tc-99m on standard medical cyclotrons.